Biography

Professor Jenna Gregory BSc MSc MMedSci PhD MBChir (Cantab.) FRCPath is a clinical academic and consultant histopathologist with research specializing in neurodegenerative diseases, focused on early detection and disease prevention^1-3.

She holds the position of Clinical Chair at the University of Aberdeen⁴, is a Fellow of the Royal College of Pathologists (FRCPath), serves as a Consultant Pathologist⁵ with NHS Grampian, and is the academic and clinical lead for the NHS Grampian Biobank/Tissue repository⁶.

Jenna’s research investigates the pathomechanisms of ALS-FTSD and other neurodegenerative diseases with a translational focus on combining early detection priorities with precision-medicine principles to empower precision-prevention strategies^7,8.

She is a qualified and internationally established researcher², clinician⁵, clinical trialist^9-12, biobanker⁶, biomarker developer^13-16, and neuroscience thought leader⁸  holding academic qualification in neuroscience (BSc, PhD), clinical trials (MSc)⁹ and molecular pathology (MMedSci)¹⁷, with professional qualifications in medicine (MBChir) and pathology (FRCPath).

Education and medical training

Jenna Gregory was born on 22 January 1984 in Stockport, Greater Manchester, UK.  Jenna began her medical degree at the University of St Andrews in 2003, where she obtained an intercalated BSc in Neuroscience in 2007.

In 2008, Jenna transferred to the University of Cambridge as part of the MD PhD programme, and obtained her PhD in Chemistry and Medicine in 2011 under the supervision of Sir Chris Dobson¹⁸ FRS FMedSci FRSC. She qualified with her medical degree (MB Chir. ) from Cambridge in 2013.

In 2013, Jenna was accepted on to the prestigious academic foundation programme at the University of Edinburgh, and alongside her full-time clinical training obtained a part-time MSc in Clinical Trials⁹ (2013-2016), and a MMedSci in Molecular Pathology¹⁷ (2016-2017) with funding from Biogen and the MRC. Jenna began specialist training in pathology in 2017.

In 2018, Jenna established her independent research group as a clinical lecturer in at the University of Edinburgh having been awarded a Scottish Clinical Research Excellence Development Scheme (SCREDS) Clinical Lectureship²⁰ that year, followed in 2020 by a Jean Shanks Foundation Grant¹ and a Pathological Society Clinical Lecturer Support Grant¹.

Jenna moved to Aberdeen in 2022, establishing her research group as a Senior Lecturer at the Institute of Medical Sciences of the University of Aberdeen. She qualified as a consultant histopathologist (FRCPath) in 2021, and began practicing as a consultant histopathologist with NHS Grampian in 2022⁵. She became the clinical lead for the NHS Grampian Biorepository/Tissue bank⁶ in 2023. Jenna became Clinical Professor at the University of Aberdeen⁴ in 2024.

Research and Career

St. Andrews (2003-2008)

As part of an intercalated medical degree at the University of St. Andrews, Jenna obtained a BSc in Neuroscience in 2007 with project thesis supervised by Prof. Jim Aiton working on the chaperone peroxiredoxin II, entitled “Over-expression of peroxiredoxin II protects cultured SK-N-SH cells from amyloid-beta toxicity”.

Cambridge (2008-2013)

Jenna moved to the University of Cambridge in 2008 as part of the MD PhD programme. working out of the Departments of Genetics and Chemistry, Jenna obtained her PhD in Chemistry and Medicine in 2011 under the supervision of Sir Chris Dobson¹⁸ FRS FMedSci FRSC with thesis entitled “Investigating the role of TDP-43 aggregation in the pathogenesis of ALS and FTD-U”.

As part of her PhD at the University of Cambridge, Jenna created and published one of the first TDP-43 Drosophila melanogaster animal models for preclinical research in amyotrophic lateral sclerosis²¹, and showed that the molecular chaperone Clusterin could also participate in intracellular aggregation events rescuing TDP-43 pathology in a paper²² that was later published in 2017.

Edinburgh (2013-2022)

Jenna moved to the University of Edinburgh as part of the prestigious academic foundation programme in 2013. Alongside her full-time clinical training on this programme Jenna obtained a part-time MSc in Clinical Trials (2013-2016) with thesis titled, “A systematic approach to identify oral neuroprotective interventions for motor neuron disease”⁹.

As part of her MSc in Clinical Trials, and to inform drug selection for MND SMART²³ (Motor Neuron Disease – Systematic Multi-arm Adaptive Randomised Trial), Jenna undertook a large systematic review and meta-analysis of all published literature in neurodegenerative disease (study protocol published in Evidence-based Preclinical Medicine in 2016²⁴). This study included >14,000 human and animal model publications screened for relevance, with data extracted from 396 studies with findings presented in Jenna’s MSc thesis, “A systematic approach to identify oral neuroprotective interventions for motor neuron disease”⁹ – therein, Jenna identified memantine as the leading drug candidate for oral intervention in MND, leading to the data-driven selection of memantine as one of the first two drugs (along with trazadone)²⁵ trialled in MND-SMART²³, which recruited its first patient on 27/02/2020¹⁰.

In her capacity as a qualified clinical trialist, Jenna contributed to the initial versions of the trial protocol and the ethics submission for MND-SMART²³ (Motor Neuron Disease – Systematic Multi-arm Adaptive Randomised Trial), the first adaptive multi-arm clinical trial for a neurodegenerative disease in the world, which in 2018 received a  £1.5 million investment from MND Scotland²⁶ to establish the UK-wide MND-SMART clinical trial²³,  and whose ethics submission was approved by the West of Scotland Research Ethics Committee on 2 October 2019²⁷.

Recognising the important contribution of molecular stratification in oncology clinical trials, alongside the relative absence of molecular markers in neurodegeneration, Jenna undertook a an MMedSci in Molecular Pathology¹⁷ (2016-2017) with funding from Biogen¹ and the MRC¹. Jenna went to Karolinska Institute to learn spatial sequencing techniques (later to become 10X sequencing) in the lab of Joakim Lundberg, producing her thesis “Interrogating the spatial transcriptome of motor neurone disease”¹⁷, in 2017.

In 2018, Jenna established her independent research group as a clinical lecturer in at the University of Edinburgh having been awarded a SCREDS Clinical Lectureship²⁰. This was followed in 2019 by a Scottish Universities Life Sciences Alliance (SULSA) Postdoctoral and Early Career Researcher Exchange Scheme (PECRE) award²⁸ to train at the New York Genome Centre/ Colombia University for the project ‘Interrogating the spatial transcriptome of cognition in ALS patients’.  In 2020 Jenna was awarded a Jean Shanks Foundation Grant¹ and a Pathological Society Clinical Lecturer Support Grant¹.

Aberdeen (2022-present)

Jenna moved to Aberdeen in 2022, establishing her research group as a Senior Lecturer at the Institute of Medical Sciences of the University of Aberdeen, with a translational focus on precision-prevention and precision medicine in neurodegenerative diseases¹⁹.

In 2022 Jenna qualified as a consultant histopathologist (FRCPath) in 2021, and a was awarded a Target ALS Early-Stage Clinician Grant²⁹. She became the clinical lead for the NHS Grampian Biorepository/Tissue bank⁶ in 2023, and became Clinical Professor at the University of Aberdeen⁴ in 2024.

Research themes

Themes in Jenna’s research in neurodegenerative diseases include; 1) ALS pathomechanisms and protein aggregation^{13-16,21,30-33}, 2) biomarkers and molecular diagnostics^13-16,34-37, 3) neuroinflammation and immune mechanisms^38-41, 4) cognitive impairment^{32,35,37,38,42-46}, 5) machine learning and AI in ALS research^{12,35,37,40,47}, 6) clinical trials and drug repurposing^9-12,24, 7) spatial transcriptomics^17,43-45, 8) epidemiological studies in ALS^35,48,49, 9) biophysics and structural biology^16,34, 10) disease heterogeneity: stratification and precision medicine^{34,37,40,45,50}, 11) RNA biology and mRNA localisation^30,51, 11) ALS genetics and molecular mechanisms^52-54, 12) cell energetics, proteostasis, stress and cell phenotypes^{21,42,45,47,54-59}, resources and methods in histopathology^60-62.

Funding

Jenna’s research has been funded by Target ALS^29,63,64, MND Association⁶⁵, LifeArc,  National Institutes of Health⁶⁶, MND Scotland^7,67, Jean Shanks Foundation, Scottish Universities Life Science Alliance²⁸, UKRI/Medical Research Council⁶⁸, MND Scotland and Scottish Government’s Chief Scientist Office^69,70, The Royal Society, Chan Zuckerberg Initiative, Pathological Society, Academy of Medical Sciences.

Bibliography

1.             Jenna Gregory ORCID 0000-0003-3337-4079 https://orcid.org/my-orcid?orcid=0000-0003-3337-4079.  ORCID: Open Researcher and Contributor ID.

2.             Jenna Gregory’s publications indexed by Google Scholar https://scholar.google.com/citations?user=LI1jAZEAAAAJ&hl=en.

3.             Jenna Gregory’s publications indexed by PubMed https://pubmed.ncbi.nlm.nih.gov/?term=jenna+m+gregory.

4.             Jenna M Gregory. Clinical Professor at the University of Aberdeen https://www.abdn.ac.uk/people/jenna.gregory.

5.             GMC General Medical Council Specialist Register: Jenna Gregory. https://www.gmc-uk.org/registrants/7414268.

6.             NHS Grampian Biorepository https://www.biorepository.nhsgrampian.org/.

7.             Gregory, J.M. (2024). How can we improve treatment success in MND? – Jenna Gregory | MND Scotland LEARN 2024 https://www.youtube.com/watch?v=kEXcDtMLKTI&t=25s.

8.             Gregory, J.M. (2025). LifeARC podium presentation: Developing novel tools to measure TDP43 in MND. https://www.youtube.com/watch?v=sdQzdCCJUT0. LifeArc – 1st Translational Science Summit on MND & Rare Dementias.

9.             Gregory, J.M. (2016). A systematic approach to identify oral neuroprotective interventions for motor neuron disease. https://figshare.com/articles/thesis/Gregory2016_MSc_Thesis_ClinTrials_UEdinburgh_A_systematic_approach_to_identify_oral_neuroprotective_interventions_for_motor_neuron_disease_pdf/29149673?file=54838550. MSc (University of Edinburgh).

10.          Wong, C., Dakin, R.S., Williamson, J., Newton, J., Steven, M., Colville, S., Stavrou, M., Gregory, J.M., Elliott, E., Mehta, A.R., et al. (2022). Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open 12, e064173. 10.1136/bmjopen-2022-064173.

11.          Wong, C., Gregory, J.M., Liao, J., Egan, K., Vesterinen, H.M., Ahmad Khan, A., Anwar, M., Beagan, C., Brown, F.S., Cafferkey, J., et al. (2023). Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus. BMJ Open 13, e064169. 10.1136/bmjopen-2022-064169.

12.          Wong, C., Gregory, J.M., Liao, J., Egan, K., Vesterinen, H.M., Khan, A.A., Anwar, M., Beagan, C., Brown, F., Cafferkey, J., et al. (2022). A Systematic Approach to Identify Neuroprotective Interventions for Motor Neuron Disease. medRxiv, 2022.2004.2013.22273823. 10.1101/2022.04.13.22273823.

13.          Spence, H., Waldron, F.M., Saleeb, R.S., Brown, A.-L., Rifai, O.M., Gilodi, M., Read, F., Roberts, K., Milne, G., Wilkinson, D., et al. (2024). RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS. Acta Neuropathologica 147, 50. 10.1007/s00401-024-02705-1.

14.          Waldron, F.M., Langerová, T., Read, F.L., Spence, H., Hanna, K., Roberts, K., Pattle, S.B., and Gregory, J.M. (2025). Improved detection of pre-symptomatic, non-central nervous system TDP-43 pathology in amyotrophic lateral sclerosis using RNA aptamer. bioRxiv, 2025.2004.2010.648122. 10.1101/2025.04.10.648122.

15.          Zacco, E., Gilodi, M., Armaos, A., Waldron, F.M., Rupert, J., Schneider, N., Gregory, J.M., and Tartaglia, G.G. (2025). Computationally Designed RNA Aptamers Enable Selective Detection of FUS Pathology in ALS. bioRxiv, 2025.2004.2030.651570. 10.1101/2025.04.30.651570.

16.          Zacco, E., Kantelberg, O., Milanetti, E., Armaos, A., Panei, F.P., Gregory, J., Jeacock, K., Clarke, D.J., Chandran, S., Ruocco, G., et al. (2022). Probing TDP-43 condensation using an in silico designed aptamer. Nature Communications 13, 3306. 10.1038/s41467-022-30944-x.

17.          Gregory, J.M. (2017). Interrogating the spatial transcriptome of motor neurone disease. https://figshare.com/articles/thesis/Gregory2017_MMedSci_Thesis_MolPath_Interrogating_the_spatial_transcriptome_of_motor_neurone_disease_pdf/29149670?file=54838136. MMedSci (University of Edinburgh).

18.          Sir Chrisopher Martin Dobson FRS FMedSci FRSC https://en.wikipedia.org/wiki/Chris_Dobson#cite_ref-cv_2-14.

19.          Gregory Lab Homepage. https://gregorylaboratory.com/.

20.          Gregory, J.M. (2018). SCREDS Clinical Lectureship – Euan MacDonald Centre People. https://euanmacdonaldcentre.org/people/dr-jenna-gregory.

21.          Gregory, J.M., Barros, T.P., Meehan, S., Dobson, C.M., and Luheshi, L.M. (2012). The aggregation and neurotoxicity of TDP-43 and its ALS-associated 25 kDa fragment are differentially affected by molecular chaperones in Drosophila. PLoS One 7, e31899. 10.1371/journal.pone.0031899.

22.          Gregory, J.M., Whiten, D.R., Brown, R.A., Barros, T.P., Kumita, J.R., Yerbury, J.J., Satapathy, S., McDade, K., Smith, C., Luheshi, L.M., et al. (2017). Clusterin protects neurons against intracellular proteotoxicity. Acta Neuropathol Commun 5, 81. 10.1186/s40478-017-0481-1.

23.          MND-SMART MND-SMART Homepage. https://mnd-smart.org/.

24.          Gregory, J.M., Waldron, F.M., Soane, T., Fulton, L., Leighton, D., Chataway, J., Pal, S., Chandran, S., and Macleod, M.R. (2016). Protocol for a systematic review and meta-analysis of experimental models of amyotrophic lateral sclerosis. Evidence-based Preclinical Medicine 3, e00023. 10.1002/ebm2.23.

25.          MND-SMART (2020). MND-SMART Study Record v1 (clinicaltrials.gov) 2020-03-06 https://clinicaltrials.gov/study/NCT04302870?tab=history&a=1#version-content-panel.

26.          MND-SMART (2018). MND Scotland: “Ground-breaking MND drug trial launched” https://mndscotland.org.uk/research/take-part/.

27.          NHS Health Research Authority. MND-SMART: Research Ethics Commitee Reference 19/WS/0123. https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/mnd-smart/.

28.          Scottish Universities Life Sciences Alliance (SULSA) Postdoctoral and Early Career Researcher Exchange Scheme (PECRE) Award: Previously Funded Exchanges (Jenna Gregory). https://sulsa.ac.uk/postdoc-exchanges/.

29.          Target ALS. Breakthroughs in Biomarker Research: Insights From Our 2024 Annual Meeting. https://www.targetals.org/2024/06/28/breakthroughs-in-als-biomarker-research/.  (2024).

30.          Barton, S.K., Gregory, J.M., Selvaraj, B.T., McDade, K., Henstridge, C.M., Spires-Jones, T.L., James, O.G., Mehta, A.R., Story, D., Burr, K., et al. (2021). Dysregulation in Subcellular Localization of Myelin Basic Protein mRNA Does Not Result in Altered Myelination in Amyotrophic Lateral Sclerosis. Front Neurosci 15, 705306. 10.3389/fnins.2021.705306.

31.          Barton, S.K., Magnani, D., James, O.G., Livesey, M.R., Selvaraj, B.T., James, O.T., Perkins, E.M., Gregory, J.M., Cleary, E., Ausems, C.R.M., et al. (2021). Transactive response DNA-binding protein-43 proteinopathy in oligodendrocytes revealed using an induced pluripotent stem cell model. Brain Commun 3, fcab255. 10.1093/braincomms/fcab255.

32.          Cassel, R., Lorenc, F., Bombardier, A., De Tapia, C., Dieterle, S., Gouveia Roque, C., Jackson, C.A., Stuart-Lopez, G., Rouaux, C., Guillot, S.J., et al. (2025). FUS Mislocalization Rewires a Cortical Gene Network to Drive Cognitive and Behavioral Impairment in ALS. medRxiv, 2025.2006.2016.25329673. 10.1101/2025.06.16.25329673.

33.          Pattle, S.B., O’Shaughnessy, J., Kantelberg, O., Rifai, O.M., Pate, J., Nellany, K., Hays, N., Arends, M.J., Horrocks, M.H., Waldron, F.M., and Gregory, J.M. (2023). pTDP-43 aggregates accumulate in non-central nervous system tissues prior to symptom onset in amyotrophic lateral sclerosis: a case series linking archival surgical biopsies with clinical phenotypic data. The Journal of Pathology: Clinical Research 9, 44-55. https://doi.org/10.1002/cjp2.297.

34.          Cox, D., Burke, M., Milani, S., White, M.A., Waldron, F.M., Böken, D., Lobanova, E., Sreedharan, J., Gregory, J.M., and Klenerman, D. (2025). Fingerprinting disease-derived protein aggregates reveals unique signature of Motor Neuron Disease. bioRxiv, 2025.2003.2004.641150. 10.1101/2025.03.04.641150.

35.          Johnson, H., Longden, J., Cameron, G., Waiter, G.D., Waldron, F.M., Gregory, J.M., and Spence, H. (2025). Machine learning identifies routine blood tests as accurate predictive measures of pollution-dependent poor cognitive function. bioRxiv, 2025.2001.2010.632396. 10.1101/2025.01.10.632396.

36.          Majumder, V., Gregory, J.M., Barria, M.A., Green, A., and Pal, S. (2018). TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol 18, 90. 10.1186/s12883-018-1091-7.

37.          Xia, Y., Gregory, J.M., Waldron, F.M., Spence, H., and Vallejo, M. (2024). Integrating Transfer Learning and Attention Mechanisms for Accurate ALS Diagnosis and Cognitive Impairment Detection. medRxiv. 10.1101/2024.09.22.24313406.

38.          Banerjee, P., Elliott, E., Rifai, O.M., O’Shaughnessy, J., McDade, K., Abrahams, S., Chandran, S., Smith, C., and Gregory, J.M. (2022). NLRP3 inflammasome as a key molecular target underlying cognitive resilience in amyotrophic lateral sclerosis. J Pathol 256, 262-268. 10.1002/path.5846.

39.          Jiwaji, Z., Tiwari, S.S., Avilés-Reyes, R.X., Hooley, M., Hampton, D., Torvell, M., Johnson, D.A., McQueen, J., Baxter, P., Sabari-Sankar, K., et al. (2022). Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology. Nature Communications 13, 135. 10.1038/s41467-021-27702-w.

40.          Rifai, O.M., Longden, J., O’Shaughnessy, J., Sewell, M.D.E., Pate, J., McDade, K., Daniels, M.J.D., Abrahams, S., Chandran, S., McColl, B.W., et al. (2022). Random forest modelling demonstrates microglial and protein misfolding features to be key phenotypic markers in C9orf72-ALS. The Journal of Pathology 258, 366-381. https://doi.org/10.1002/path.6008.

41.          Rifai, O.M., O’Shaughnessy, J., Dando, O.R., Munro, A.F., Sewell, M.D.E., Abrahams, S., Waldron, F.M., Sibley, C.R., and Gregory, J.M. (2023). Distinct neuroinflammatory signatures exist across genetic and sporadic amyotrophic lateral sclerosis cohorts. Brain, awad243. 10.1093/brain/awad243.

42.          Gregory, J.M., Elliott, E., McDade, K., Bak, T., Pal, S., Chandran, S., Abrahams, S., and Smith, C. (2020). Neuronal clusterin expression is associated with cognitive protection in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology 46, 255-263. https://doi.org/10.1111/nan.12575.

43.          Gregory, J.M., McDade, K., Livesey, M.R., Croy, I., Marion de Proce, S., Aitman, T., Chandran, S., and Smith, C. (2020). Spatial transcriptomics identifies spatially dysregulated expression of GRM3 and USP47 in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology 46, 441-457. 10.1111/nan.12597.

44.          Mehta, A.R., Selvaraj, B.T., Barton, S.K., McDade, K., Abrahams, S., Chandran, S., Smith, C., and Gregory, J.M. (2020). Improved detection of RNA foci in C9orf72 amyotrophic lateral sclerosis post-mortem tissue using BaseScope™ shows a lack of association with cognitive dysfunction. Brain Commun 2, fcaa009. 10.1093/braincomms/fcaa009.

45.          Petrescu, J., Roque, C.G., Jackson, C.A., Daly, A., Kang, K., Casel, O., Leung, M., Reilly, L., Eschbach, J., McDade, K., et al. (2025). Differential Cellular Mechanisms Underlie Language and Executive Decline in Amyotrophic Lateral Sclerosis. bioRxiv, 2025.2002.2026.640433. 10.1101/2025.02.26.640433.

46.          Rifai, O.M., Waldron, F.M., Shaughnessy, J., Read, F.L., Gilodi, M., Pastore, A., Shneider, N., Tartaglia, G.G., Zacco, E., Spence, H., and Gregory, J. (2024). Amygdala TDP-43 pathology is associated with behavioural dysfunction and ferritin accumulation in amyotrophic lateral sclerosis. bioRxiv, 2024.2006.2001.596819. 10.1101/2024.06.01.596819.

47.          Krispin, S., van Zuiden, W., Danino, Y.M., Molitor, L., Rudberg, N., Bar, C., Coyne, A., Meimoun, T., Waldron, F.M., Gregory, J.M., et al. (2025). Organellomics: AI-driven deep organellar phenotyping reveals novel ALS mechanisms in human neurons. bioRxiv, 2024.2001.2031.572110. 10.1101/2024.01.31.572110.

48.          Elliott, E., Newton, J., Rewaj, P., Gregory, J.M., Tomarelli, L., Colville, S., Chandran, S., and Pal, S. (2020). An epidemiological profile of dysarthria incidence and assistive technology use in the living population of people with MND in Scotland. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21, 116-122. 10.1080/21678421.2019.1672748.

49.          Leighton, D.J., Ansari, M., Newton, J., Parry, D., Cleary, E., Colville, S., Stephenson, L., Larraz, J., Johnson, M., Beswick, E., et al. (2023). Genotype–phenotype characterisation of long survivors with motor neuron disease in Scotland. Journal of Neurology. 10.1007/s00415-022-11505-0.

50.          Rifai, O.M., O’Shaughnessy, J., Dando, O.R., Munro, A.F., Sewell, M.D.E., Abrahams, S., Waldron, F.M., Sibley, C.R., and Jm, G. (2023). Distinct neuroinflammatory signatures exist across genetic and sporadic ALS cohorts. bioRxiv. 10.1101/2023.01.19.524561.

51.          Barton, S.K., Gregory, J.M., Chandran, S., and Turner, B.J. (2019). Could an Impairment in Local Translation of mRNAs in Glia be Contributing to Pathogenesis in ALS? Front Mol Neurosci 12, 124. 10.3389/fnmol.2019.00124.

52.          Gregory, J.M., Fagegaltier, D., Phatnani, H., and Harms, M.B. (2020). Genetics of Amyotrophic Lateral Sclerosis. Current Genetic Medicine Reports 8, 121-131. 10.1007/s40142-020-00194-8.

53.          Rifai, O.M., Waldron, F.M., Sleibi, D., O’Shaughnessy, J., Leighton, D.J., and Gregory, J.M. (2024). Clinicopathological analysis of NEK1 variants in amyotrophic lateral sclerosis. Brain Pathology n/a, e13287. https://doi.org/10.1111/bpa.13287.

54.          Selvaraj, B.T., Livesey, M.R., Zhao, C., Gregory, J.M., James, O.T., Cleary, E.M., Chouhan, A.K., Gane, A.B., Perkins, E.M., Dando, O., et al. (2018). C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca(2+)-permeable AMPA receptor-mediated excitotoxicity. Nat Commun 9, 347. 10.1038/s41467-017-02729-0.

55.          Crippa, V., Cicardi, M.E., Ramesh, N., Seguin, S.J., Ganassi, M., Bigi, I., Diacci, C., Zelotti, E., Baratashvili, M., Gregory, J.M., et al. (2016). The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. Hum Mol Genet 25, 3908-3924. 10.1093/hmg/ddw232.

56.          Elliott, E., Bailey, O., Waldron, F.M., Hardingham, G.E., Chandran, S., and Gregory, J.M. (2020). Therapeutic Targeting of Proteostasis in Amyotrophic Lateral Sclerosis-a Systematic Review and Meta-Analysis of Preclinical Research. Front Neurosci 14, 511. 10.3389/fnins.2020.00511.

57.          Gregory, J.M., Livesey, M.R., McDade, K., Selvaraj, B.T., Barton, S.K., Chandran, S., and Smith, C. (2020). Dysregulation of AMPA receptor subunit expression in sporadic ALS post-mortem brain. J Pathol 250, 67-78. 10.1002/path.5351.

58.          Mehta, A.R., Gregory, J.M., Dando, O., Carter, R.N., Burr, K., Nanda, J., Story, D., McDade, K., Smith, C., Morton, N.M., et al. (2021). Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol 141, 257-279. 10.1007/s00401-020-02252-5.

59.          Mehta, A.R., Walters, R., Waldron, F.M., Pal, S., Selvaraj, B.T., Macleod, M.R., Hardingham, G.E., Chandran, S., and Gregory, J.M. (2019). Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Brain Commun 1, fcz009. 10.1093/braincomms/fcz009.

60.          Waldron, F.M., and Jm, G. (2024). An adaptable protocol for antibody & TDP-43 RNA aptamer dual immunohistochemical staining for FFPE-preserved human tissue: with SOP and tick-sheet. https://www.protocols.io/view/an-adaptable-protocol-for-antibody-amp-tdp-43-rna-yxmvm97k6l3p/v1. protocols.io. dx.doi.org/10.17504/protocols.io.yxmvm97k6l3p/v1.

61.          Waldron, F.M., Rifai, O.M., and Gregory, J.M. (2024). Antibody and TDP-43 RNA aptamer dual staining to detect patterns of co-pathology in FFPE-preserved human tissue, as described in Rifai et al., 2024 (Brain Pathology): A SOP and tick-sheet. V.1 https://www.protocols.io/view/antibody-and-tdp-43-rna-aptamer-dual-staining-to-d-14egn6wnml5d/v1. protocols.io. dx.doi.org/10.17504/protocols.io.14egn6wnml5d/v1.

62.          Waldron, F.M., Spence, H., and Gregory, J.M. (2024). TDP-43 RNA aptamer staining to detect pathological TDP-43 in FFPE human tissue, as described in Spence and Waldron et al., 2024 (Acta Neuropathologica): A SOP and tick-sheet. v2 https://www.protocols.io/view/tdp-43-rna-aptamer-staining-to-detect-pathological-eq2lyjo4mlx9/v2. protocols.io. 10.17504/protocols.io.eq2lyjo4mlx9/v2.

63.          Target ALS Basic Biology (Consortium) Grant: “Probing RNA-binding protein aggregates at the nanoscale using in-silico-designed aptamers” https://www.targetals.org/2025/03/04/basicbiology/.  (2022).

64.          Interview with Jenna Gregory, Ph.D., 2023 Target ALS Annual Meeting. https://www.youtube.com/watch?v=69OI3LX39pA&t=5s.  (2023).

65.          MND Association. Mapping TDP-43 and FUS pathology across motor control networks. https://www.mndassociation.org/research/our-research/research-we-fund/understanding-clinical-progression/mapping-patterns-tdp-43.  (2024).

66.          NIH NIH RO1: “The Physical Biology of Neurodegeneration in Sporadic Amyotrophic Lateral Sclerosis/Frontotemporal Dementia”. https://reporter.nih.gov/search/MgJvoeXFHU6eUacDJu0iMg/project-details/10896182#details.

67.          MND Scotland funded project to explore crucial aspect of MND. https://mndscotland.org.uk/news/mnd-scotland-funded-project-to-explore-crucial-aspect-of-neurodegenerative-diseases/.  (2022).

68.          UKRI/MRC (2023). NanoString Integrated Spatial Biology Platform https://gtr.ukri.org/projects?ref=MC_PC_MR%2FY002725%2F1.

69.          MND Scotland. Clinical Academic Fellowship Announced for MND Research: Kristine Roberts (Jenna Gregory supervisor). https://mndscotland.org.uk/news/clinical-academic-fellowship-announced-for-mnd-research/.  (2024).

70.          CSO (2024). Scottish Government’s Chief Scientist Office Clinical Academic Fellowship to Kristine Roberts (Jenna Gregory supervisor). https://www.cso.scot.nhs.uk/funded-research/fellowships/caf/.